Scilex Pharmaceuticals

Scilex Pharmaceuticals pertence à Sorrento Therapeutics.

Sorrento Therapeutics é uma empresa listada sob o símbolo SRNE (US).

Veja o organograma con seus 12 executivos principais

Biografias mais buscadas da Scilex Pharmaceuticals

• Jaisim Shah, Chief Executive Officer and Director
• Jay Chun, Director
• Laura Hamill, Director

Recentes movimentos de executivos em Scilex Pharmaceuticals

• Elizabeth Czerepak, Executive Vice President, Chief Financial Officer and Chief Business Officer, deixou a Companhia  (Notícia publicada em 25 de setembro de 2023).
• Stephen Ma antes Chief Accounting Officer, foi promovido a Chief Financial Officer  (Notícia publicada em 25 de setembro de 2023).
• Tien Lee, Director, deixou a Companhia  (Notícia publicada em 6 de setembro de 2023).

Criar um alerta
para seguir os movimentos de executivos da Scilex Pharmaceuticals.

Sorrento Therapeutics possui 1.860 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).

Popular M&A news in Farmacêutica

• MedMen has filed for bankruptcy protection  (publicado em 28 de abril de 2024).
• AstraZeneca has announced the acquisition of Fusion Pharma  (publicado em 23 de março de 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (publicado em 19 de março de 2024).

Outros contatos sugeridos na indústria do Farmacêutica

• Jean-Frédéric Paulsen - Executive Chairman of the Board da Ferring Pharmaceuticals
• Thierry Abribat - Chief Executive Officer da Amolyt Pharma
• Emma Walmsley - Chief Executive Officer and Director da GSK

Saiba mais sobre a indústria do Farmacêutica >

Últimos comunicados de imprensa de Scilex Pharmaceuticals

• News & Events – Scilex Holding
• News & Events - Scilex Holding
• News - Scilex Holding
• Scilex Announces Addition of ZTlido® to Express Scripts National Formularies - Scilex Holding
• Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives – SCILEX Pharmaceutical
• Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management – SCILEX Pharmaceutical
• Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion – SCILEX Pharmaceutical
• Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndr
• Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020 – SCILEX Pharmaceutical
• Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released – SCILEX Pharmaceutical
• View more press releases Close

Redes sociais sobre Scilex Pharmaceuticals

• Scilex Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Scilex Pharmaceuticals na LinkedIn, Twitter e YouTube

Contate seus executivos por e-mail agora, incluindo Jaisim Shah

Ligue para a Scilex Pharmaceuticals em +1 610...

Veja o organograma

Register to receive your alert

Relatório um erro